GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Psychemedics Corp (NAS:PMD) » Definitions » 5-Year RORE %

Psychemedics (Psychemedics) 5-Year RORE % : 35.92% (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Psychemedics 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Psychemedics's 5-Year RORE % for the quarter that ended in Dec. 2023 was 35.92%.

The industry rank for Psychemedics's 5-Year RORE % or its related term are showing as below:

PMD's 5-Year RORE % is ranked better than
88.37% of 172 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.83 vs PMD: 35.92

Psychemedics 5-Year RORE % Historical Data

The historical data trend for Psychemedics's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psychemedics 5-Year RORE % Chart

Psychemedics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.22 2,737.14 142.03 57.78 35.92

Psychemedics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.78 49.37 44.25 46.10 35.92

Competitive Comparison of Psychemedics's 5-Year RORE %

For the Diagnostics & Research subindustry, Psychemedics's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psychemedics's 5-Year RORE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Psychemedics's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Psychemedics's 5-Year RORE % falls into.



Psychemedics 5-Year RORE % Calculation

Psychemedics's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.72-0.274 )/( -1.467-1.3 )
=-0.994/-2.767
=35.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


Psychemedics  (NAS:PMD) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Psychemedics 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Psychemedics's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Psychemedics (Psychemedics) Business Description

Traded in Other Exchanges
N/A
Address
289 Great Road, Suite 200, Acton, MA, USA, 01720
Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. Geographically it generates the majority of its revenue from the United States.
Executives
Shannon Shoemaker officer: Chief Revenue Officer 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Charles M Doucot officer: Executive Vice President 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Andrew Reynolds director C/O FLEETMATICS, 1100 WINTER STREET, 4TH FL, WALTHAM MA 02451
Brian Hullinger director, officer: President & CEO 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Robyn C Davis director ONE WALLINGFORD ROAD, MARBLEHEAD MA 01945
Michael Weisenhoff other: Assistant Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Michael I Schaffer officer: VP of Laboratory Operations C/O PAYCHEMEDICS CORP, 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
William B. Norris other: Assistant Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Darius G Nevin other: See Footnote 1 C/O WCI COMMUNITIES, INC., 24301 WALDEN CENTER DRIVE, BONITA SPRINGS FL 34134
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Andrew Limbek officer: Vice President & Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Fred J Weinert director 330 E MAIN ST, BARRINGTON IL 60620
Kubacki Raymond C Jr director, officer: Chairman, CEO & President 125 NAGOG PARK, ACTON MA 01720
A Clinton Allen director, officer: Chairman 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
Neil Lerner officer: VP - Finance C/O PSYCHEMEDICS CORPORATION, 125 NAGOG PARK, ACTON MA 01720

Psychemedics (Psychemedics) Headlines

From GuruFocus